NCT01765426View on ClinicalTrials.gov

Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

February 15, 2013

Primary Completion Date

June 26, 2014

Study Completion Date

June 26, 2014

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

TDV

TDV suspension for intradermal administration

DRUG

Placebo

Phosphate buffered saline (PBS)

Trial Locations (2)

77555

University of Texas Medical Branch, Galveston

98101

Group Health Research Institute, Seattle

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Takeda

INDUSTRY